Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Results Support First-Line T-DM1 in HER2+ Breast Cancer

Key clinical point: Final results from the MARIANNE trial revealed similar overall survival times in patients who received trastuzumab emtansine (T-DM1), T-DM1 plus pertuzumab, or trastuzumab plus a taxane (HT).

Major finding: The median overall survival was 50.9 months in the HT arm, 53.7 months in the T-DM1 arm, and 51.8 months in the T-DM1 plus pertuzumab arm.

Study details: Phase 3 trial of 1,095 patients with HER2-positive, advanced breast cancer.

Disclosures: This study was funded by F. Hoffmann–La Roche. The researchers disclosed relationships with Roche and other companies.

Citation:

Perez EA et al. Cancer. 2019 Jul 18. doi: 10.1002/cncr.32392.